Regeneron Pharmaceuticals, Inc. (0R2M.L)
| Previous close | 1,039.46 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 1,962 |
| Market cap | 115.048B |
| Beta (5Y monthly) | 0.13 |
| PE ratio (TTM) | 0.15 |
| EPS (TTM) | 70.31 |
| Earnings date | 01 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksRegeneron (REGN), SNY Win EC Approval for Dupixent for COPD
Regeneron (REGN) and partner Sanofi get approval for their blockbuster drug Dupixent for the chronic obstructive pulmonary disease indication in the EU.
GlobeNewswireDupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved lung function and also improved health-related quality of life Dupixent is the first new treatment approach for COPD in more than a decade and a new option for approximately 220,000 adults in the European Union (EU) Approval represents the sixth approved indication for Dupixent in the EU and seventh
GuruFocus.comInsider Sale: Director Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc (REGN)
The transaction was documented in an SEC Filing. Following this transaction, the insider now owns 17,882 shares of Regeneron Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
